Internal Reference Number: FOI_6817
Date Request Received: 11/10/2022 00:00:00
Date Request Replied To: 28/10/2022 00:00:00
This response was sent via: By Email
Request Summary: Biologic medicines in gastroenterology
Request Category: Companies
| Question Number 1: How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Ozanimod • Tofacitinib • Ustekinumab • Vedolizumab | |
| Answer To Question 1: Adalimumab Humira 11 Adalimumab biosimilar 61 Filgotinib 0 Golimumab <5 Infliximab Remicade 13 Infliximab biosimilar 127 Ozanimod 0 Tofacitinib <5 Ustekinumab 35 Vedolizumab 39 | |
| Question Number 2: If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Ozanimod • Tofacitinib • Ustekinumab • Vedolizumab | |
| Answer To Question 2: No of patients treated in the last 3 months for Ulcerative colitis ONLY with: Adalimumab/Humira <5 Adalimumab Bio similar (Amgevita / Imraldi) 20 Filgotinib 0 Golimumab <5 Infliximab/Remicade 5 Infliximab Biosimilar (Inflectra) 44 Ozanimod 0 Tofacitinib <5 Ustekinumab 8 Vedolizumab 22 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
